Conditional green light for Allos drug | Chemical & Engineering News
Volume 82 Issue 23 | p. 12 | Concentrates
Issue Date: June 7, 2004

Conditional green light for Allos drug

Department: Business

FDA has granted Allos Therapeutics conditional approval for RSR13 (efaproxiral), a drug that treats brain metastases originating from breast cancer. Approval is dependent on results of an ongoing Phase III clinical trial and inspection of Allos' manufacturing facility. The nod is a surprise, given that last month an FDA committee recommended against approval of RSR13, expressing concerns that a previous clinical test on a non-cancer-specific test group involved too few patients with breast cancer (C&EN, May 10, page 12). RSR13 is manufactured for Allos under contract by Hovione.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment